CN104274746B - Pharmaceutical composition for treating pharyngitis - Google Patents
Pharmaceutical composition for treating pharyngitis Download PDFInfo
- Publication number
- CN104274746B CN104274746B CN201410539047.5A CN201410539047A CN104274746B CN 104274746 B CN104274746 B CN 104274746B CN 201410539047 A CN201410539047 A CN 201410539047A CN 104274746 B CN104274746 B CN 104274746B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- radix
- pharyngitis
- rehmannia
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 50
- 201000007100 Pharyngitis Diseases 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 31
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 15
- 244000012254 Canarium album Species 0.000 claims abstract description 15
- 235000009103 Canarium album Nutrition 0.000 claims abstract description 15
- 241000931705 Cicada Species 0.000 claims abstract description 15
- 241000596154 Belamcanda Species 0.000 claims abstract description 14
- 230000001154 acute effect Effects 0.000 claims abstract description 4
- 208000016150 acute pharyngitis Diseases 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 241000405414 Rehmannia Species 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 16
- 239000003826 tablet Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 240000005250 Chrysanthemum indicum Species 0.000 claims description 14
- 235000018959 Chrysanthemum indicum Nutrition 0.000 claims description 14
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 240000002948 Ophiopogon intermedius Species 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 241001412627 Adenophora liliifolia Species 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000012467 final product Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 238000004064 recycling Methods 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 229940126678 chinese medicines Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 15
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241001061264 Astragalus Species 0.000 abstract 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 abstract 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- 206010014025 Ear swelling Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010018691 Granuloma Diseases 0.000 description 4
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 230000006020 chronic inflammation Effects 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 150000002989 phenols Chemical class 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 3
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940067131 aspirin 100 mg Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- -1 sublimed preparation Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The invention belongs to the technical field of medicines and particularly relates to a pharmaceutical composition for treating pharyngitis, a preparation method of the pharmaceutical composition and a use of the pharmaceutical composition in preparation of a medicine for treating pharyngitis. The pharmaceutical composition provided by the invention comprises the following components: radix rehmanniae, wild chrysanthemum flower, radix ranunculi ternate, trigone, Chinese olive, radix ophiopogonis, astragalus, radix adenophorae, radix polygonati officinalis, blackberry lily, cicada slough and honeysuckle. The pharmaceutical composition has a good effect of treating pharyngitis and particularly acute/chronic pharyngitis, and the drug has a small toxic side effect, thereby being capable of being clinically promoted.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to it is a kind of treat pharmaceutical composition of pharyngitis and preparation method thereof and
Its purposes in pharyngitis medicine is treated.
Background technology
Pharyngitis is under pharyngeal mucosa, mucous membrane and the diffusivity inflammation of lymphoid tissue, is often accompanied by other upper respiratory diseases, is
Very common a kind of disease of pharynx in crowd.Pharyngeal discomfort, there is foreign body sensation, always feels the pharyngeal east for having and not swallowing and can not tell
West, irritative cough dries, swells, blocking, itch etc., but few pharyngalgia.The early morning sticky phlegm block that often spues easily causes nausea.
According to theory of traditional Chinese medical science, pharyngitis has acute and chronic point, but belongs to " larynx numbness " category.
Chronic pharyngitis (Chronic pharyngitis) is mainly pharynx mucous membrane chronic inflammation, and diffusivity inflammation is often above to exhale
A part for chronic other property inflammation in road is inhaled, limitation inflammation is then more with the inflammation for swallowing GALT.Chronic pharyngitis is being faced
The course of disease is more long on bed, typically more than three months, and often due to fatigue, catch a cold, the factor such as suffer from cold causes exacerbation of symptoms, dialectical
The common deficiency of Yin, the deficiency of vital energy or phlegm heat, when have wind, heat, phlegm, drink etc. concurrently, with clearing heat and detoxicating, nourishiing yin to clear away the lung-heat, fluid dryness, regulating qi-flowing for eliminating phlegm
It is a kind of common disease, frequently-occurring disease etc. method to control, it is relatively more obstinate in conventional drug therapy, and recurrent exerbation, flu exacerbation,
It is common with a middle-aged person.Show as pharyngeal mucous membrane chronic congestion.Lesion is concentrated mainly on pharyngeal mucous layer, has more around its blood vessel
Lymphoid tissue infiltrates, and also shows leucocyte and plasmocyte infiltrating.Connective tissue proliferation under mucous membrane and mucous membrane, can be with mucous gland fertilizer
Greatly, glandular secretion hyperfunction, mucilage secretion increases and more sticky.
Treatment to pharyngitis patient, treatment is probably a long-term process.If it is especially slow that people suffers from pharyngitis
Property pharyngitis, medication and prevention could will effectively control and reduce advancing of disease with for a long time, to adhere to treatment for a long time,
For the control of pharyngitis, except taking medicine on time, diet and habits and customs are also most important.
The content of the invention
The invention provides a kind of pharmaceutical composition for treating pharyngitis, the pharmaceutical composition good effect, toxic and side effect is small, it
It is obtained by following raw material：The dried rhizome of rehmannia, chrysanthemum indicum, radix ranunculi ternati, Rhizoma Sparganii, Chinese olive, the tuber of dwarf lilyturf, the Radix Astragali, the root of straight ladybell, radix polygonati officinalis, blackberry lily, cicada slough, gold
Honeysuckle flower.
Pharmaceutical composition of the present invention traditional Chinese medicinal components selection on wind-dispelling removing toxic substances, clearing heat, relieving sore-throat as main standard, to above-mentioned
The parts by weight of all taste Chinese medicine have been carried out preferably, and preferred condition is that drug matching uses increasing of the rear medicine to treating pharyngitis effect
By force.Preferably, pharmaceutical composition of the present invention is obtained by the raw material of following weight portion：Dried rhizome of rehmannia 4-13g, chrysanthemum indicum 11-15g, cat
Pawl grass 5.5-9.5g, Rhizoma Sparganii 1-8g, Chinese olive 10-30g, tuber of dwarf lilyturf 5-12g, Radix Astragali 10-18g, the root of straight ladybell 1-8g, radix polygonati officinalis 10-18g, penetrate
Dry 1-3g, cicada slough 8-16g, honeysuckle 11-25g.Used as presently most preferred embodiment of the invention, pharmaceutical composition of the present invention is by following
The raw material of weight portion is obtained：Dried rhizome of rehmannia 9g, chrysanthemum indicum 13g, radix ranunculi ternati 7.5g, Rhizoma Sparganii 5g, Chinese olive 20g, tuber of dwarf lilyturf 8g, Radix Astragali 14g, sand
Ginseng 4g, radix polygonati officinalis 14g, blackberry lily 2g, cicada slough 12g, honeysuckle 18g.
In order to preferably express pharmaceutical composition of the invention, pharmaceutical composition of the invention can be prepared into clinically normal
Formulation.Such as, the system such as powderous preparations, powder, pill, sublimed preparation, paste, granule, oral liquid, syrup, tablet, capsule
Agent.Preferably, pharmaceutical composition of the present invention is prepared into granule, tablet or capsule according to conventional fabrication process.
Present invention also offers a kind of preparation method of pharmaceutical composition described above, it mainly includes following step：Take
The taste Chinese medicine of dried rhizome of rehmannia of recipe quantity etc. 12 adds 6-8 times of decocting to boil twice, and the time is respectively 1-3 hours, merges decocting liquid twice, filter
Cross, after cooling, plus ethanol to concentration is 40-80%, stands 12-24 hours, and refluxing extraction three times, return time is 2~3h, filter
Cross, filtrate recycling ethanol, be concentrated into medicinal extract, extract dry is into fine powder；Those skilled in the art add in the preparation method technology
Enter appropriate amount of auxiliary materials and the receptible various formulations of clinical institute are made of conventional formulation method, obtain final product.
The present invention is also claimed purposes of the aforementioned pharmaceutical compositions in treatment pharyngitis medicine is prepared, and is especially preparing
Treat the purposes in acute, chronic pharyngitis medicine.
The pharmacodynamics embodiment 10 of acpuei pharyngitis shows, compares with model group, pharmaceutical composition of the present invention high, medium and low three
Individual dosage group extremely significantly or can significantly reduce the ear swelling value (P ＜ 0.01, P ＜ 0.05) of dimethylbenzene induced mice, show
Pharmaceutical composition of the present invention has the effect of the mice ear for significantly inhibiting dimethylbenzene induction, and its reduction effect to ear swelling
There is significant dose-effect relationship in fruit.Under same experiment condition, positive control drug is significantly reduced ear swelling value (P ＜ 0.01), but
Its antiphlogistic effects is substantially not as good as pharmaceutical composition high dose group of the present invention..
The effect of strengthening the body resistance to consolidate the constitution, fluid dryness effect：Select respiratory tract to promote secretion experiment to be acted on so as to explanation fluid dryness, observation
Whether institute's reagent thing can increase sputum amount, can select the phenol red experimental method of mouse.Pharmacodynamics embodiment 11 of the present invention shows, with model
Group compares, basic, normal, high each dosage group of pharmaceutical composition of the present invention can significantly or pole significantly improve mouse tracheae section phenol
Red excretion amount (P ＜ 0.05, P ＜ 0.01), shows that pharmaceutical composition of the present invention has significant phlegm-dispelling functions, and exist significant
Dose-effect relationship.Under same experiment condition, also pole significantly improves phenols contents (the P ＜ of mouse tracheae section to positive control drug
0.01)。
Chronic pharyngitis Pharmacodynamics are studied, and mainly investigate the effect such as clearing heat and detoxicating, fluid dryness.It is clearing heat and detoxicating：With thin
Subacute, the chronic inflammation processes of born of the same parents' propagation are main test index, observe the effect of medicine.Pharmacodynamics embodiment 12 of the present invention
It has been shown that, compares with model group, the present invention is high, middle dose group and aspirin control group can pole significantly reduce granulomatous weight
(P ＜ 0.01), low dose group significantly reduces granulomatous weight (P ＜ 0.05) and there is significant dose-effect relationship, and this explanation is originally
Invention pharmaceutical composition can be obvious to subacute, chronic inflammation therapeutic effect, especially present invention height, middle dosage.
The clinical and patient medical history that the present invention also have chosen hospital carries out clinical test, and acpuei pharyngitis patient 213 is treated altogether
Example, total effective rate is up to 98.12%.Wherein criterion of therapeutical effect includes following four aspect：Fully recover for Clinical symptom and sign disappears, recover
Normally；It is effective for Clinical symptom and sign substantially or mostly disappears；Effectively it is clearly better for clinical symptoms, but medication need to be continued and controls
Treat；Invalid is Clinical symptom and sign without improvement.Instructions of taking：Tablet prepared by pharmaceutical composition of the present invention is taken daily, every time 1
Piece, 2 times a day, every folding crude drug about 0.10g, takes medicine continuously 3 days.To 213 patients, carried out using pharmaceutical composition of the invention
Tracking treatment.Wherein, 192 are cured, effective 12, effective 5, invalid 4, cure rate reaches 90.14%, and total effective rate is
98.12%, so pharmaceutical composition of the present invention is the active drug for treating pharyngitis, with good clinical meaning, there is significant
Economic and social benefit.
Pharmaceutical composition of the present invention is natural pure Chinese medicinal preparation, and adverse reaction and toxic and side effect are significantly reduced, and the present invention
Pharmaceutical composition effect is comprehensive, and medication effect more preferably, significantly improves the compliance and quality of life of patient, has
Significant clinical generalization value.
Specific embodiment
The present invention is further described below by way of specific embodiment, but the present invention is not limited only to implement in detail below
Example.
Embodiment 1
Prescription：Dried rhizome of rehmannia 9g, chrysanthemum indicum 13g, radix ranunculi ternati 7.5g, Rhizoma Sparganii 5g, Chinese olive 20g, tuber of dwarf lilyturf 8g, Radix Astragali 14g, the root of straight ladybell
4g, radix polygonati officinalis 14g, blackberry lily 2g, cicada slough 12g, honeysuckle 18g.
Preparation technology：
Take the taste Chinese medicine of dried rhizome of rehmannia of recipe quantity etc. 12 plus 7 times of decoctings are boiled twice, the time is respectively 2 hours, merge twice
Decocting liquid, filtration, after cooling, plus ethanol to concentration is 60%, stands 24 hours, refluxing extraction three times, and return time is 2h, filter
Cross, filtrate recycling ethanol, be concentrated into medicinal extract, extract dry is into fine powder；Those skilled in the art add in the preparation method technology
Enter appropriate amount of auxiliary materials and be made tablet with conventional formulation method, obtain final product.
Embodiment 2
Prescription：Dried rhizome of rehmannia 9g, chrysanthemum indicum 13g, radix ranunculi ternati 7.5g, Rhizoma Sparganii 5g, Chinese olive 20g, tuber of dwarf lilyturf 8g, Radix Astragali 14g, the root of straight ladybell
4g, radix polygonati officinalis 14g, blackberry lily 2g, cicada slough 12g, honeysuckle 18g.
Preparation technology：
Take the taste Chinese medicine of dried rhizome of rehmannia of recipe quantity etc. 12 plus 7 times of decoctings are boiled twice, the time is respectively 2 hours, merge twice
Decocting liquid, filtration, after cooling, plus ethanol to concentration is 60%, stands 12 hours, refluxing extraction three times, and return time is 3h, filter
Cross, filtrate recycling ethanol, be concentrated into medicinal extract, extract dry is into fine powder；Those skilled in the art add in the preparation method technology
Enter appropriate amount of auxiliary materials and be made tablet capsule agent with conventional formulation method, obtain final product.
Embodiment 3
Prescription：Dried rhizome of rehmannia 9g, chrysanthemum indicum 13g, radix ranunculi ternati 7.5g, Rhizoma Sparganii 5g, Chinese olive 20g, tuber of dwarf lilyturf 8g, Radix Astragali 14g, the root of straight ladybell
4g, radix polygonati officinalis 14g, blackberry lily 2g, cicada slough 12g, honeysuckle 18g.
Preparation technology：
Take the taste Chinese medicine of dried rhizome of rehmannia of recipe quantity etc. 12 plus 7 times of decoctings are boiled twice, the time is respectively 2 hours, merge twice
Decocting liquid, filtration, after cooling, plus ethanol to concentration is 60%, stands 24 hours, refluxing extraction three times, and return time is 3h, filter
Cross, filtrate recycling ethanol, be concentrated into medicinal extract, extract dry is into fine powder；Those skilled in the art add in the preparation method technology
Enter appropriate amount of auxiliary materials and be made tablet and powder agent with conventional formulation method, obtain final product.
Embodiment 4
Prescription：Dried rhizome of rehmannia 9g, chrysanthemum indicum 13g, radix ranunculi ternati 7.5g, Rhizoma Sparganii 5g, Chinese olive 20g, tuber of dwarf lilyturf 8g, Radix Astragali 14g, the root of straight ladybell
4g, radix polygonati officinalis 14g, blackberry lily 2g, cicada slough 12g, honeysuckle 18g.
Preparation technology：
Take the taste Chinese medicine of dried rhizome of rehmannia of recipe quantity etc. 12 plus 7 times of decoctings are boiled twice, the time is respectively 2 hours, merge twice
Decocting liquid, filtration, after cooling, plus ethanol to concentration is 60%, stands 12 hours, refluxing extraction three times, and return time is 2h, filter
Cross, filtrate recycling ethanol, be concentrated into medicinal extract, extract dry is into fine powder；Those skilled in the art add in the preparation method technology
Enter appropriate amount of auxiliary materials and be made tablet powder with conventional formulation method, obtain final product.
Embodiment 5
Prescription：Dried rhizome of rehmannia 9g, chrysanthemum indicum 13g, radix ranunculi ternati 7.5g, Rhizoma Sparganii 5g, Chinese olive 20g, tuber of dwarf lilyturf 8g, Radix Astragali 14g, the root of straight ladybell
4g, radix polygonati officinalis 14g, blackberry lily 2g, cicada slough 12g, honeysuckle 18g.
Preparation technology：
Take the taste Chinese medicine of dried rhizome of rehmannia of recipe quantity etc. 12 plus 7 times of decoctings are boiled twice, the time is respectively 2 hours, merge twice
Decocting liquid, filtration, after cooling, plus ethanol to concentration is 60%, stands 24 hours, refluxing extraction three times, and return time is 2h, filter
Cross, filtrate recycling ethanol, be concentrated into medicinal extract, extract dry is into fine powder；Those skilled in the art add in the preparation method technology
Enter appropriate amount of auxiliary materials and be made tablet oral liquid with conventional formulation method, obtain final product.
Embodiment 6
Prescription：Dried rhizome of rehmannia 4g, chrysanthemum indicum 11g, radix ranunculi ternati 5.5g, Rhizoma Sparganii 1g, Chinese olive 10g, tuber of dwarf lilyturf 5g, Radix Astragali 10g, the root of straight ladybell
1g, radix polygonati officinalis 10g, blackberry lily 1g, cicada slough 8g, honeysuckle 11g.
Preparation technology：
Take the taste Chinese medicine of dried rhizome of rehmannia of recipe quantity etc. 12 plus 8 times of decoctings are boiled twice, the time is respectively 3 hours, merge twice
Decocting liquid, filtration, after cooling, plus ethanol to concentration is 80%, stands 24 hours, refluxing extraction three times, and return time is 3h, filter
Cross, filtrate recycling ethanol, be concentrated into medicinal extract, extract dry is into fine powder；Those skilled in the art add in the preparation method technology
Enter appropriate amount of auxiliary materials and be made tablet and powder agent with conventional formulation method, obtain final product.
Embodiment 7
Prescription：Dried rhizome of rehmannia 13g, chrysanthemum indicum 15g, radix ranunculi ternati 9.5g, Rhizoma Sparganii 8g, Chinese olive 30g, tuber of dwarf lilyturf 12g, Radix Astragali 18g, the root of straight ladybell
8g, radix polygonati officinalis 18g, blackberry lily 3g, cicada slough 16g, honeysuckle 25g.
Preparation technology：
Take the taste Chinese medicine of dried rhizome of rehmannia of recipe quantity etc. 12 plus 6 times of decoctings are boiled twice, the time is respectively 1 hour, merge twice
Decocting liquid, filtration, after cooling, plus ethanol to concentration is 40%, stands 12 hours, refluxing extraction three times, and return time is 2h, filter
Cross, filtrate recycling ethanol, be concentrated into medicinal extract, extract dry is into fine powder；Those skilled in the art add in the preparation method technology
Enter appropriate amount of auxiliary materials and be made tablet tablet with conventional formulation method, obtain final product.
Embodiment 8
Prescription：Dried rhizome of rehmannia 13g, chrysanthemum indicum 11g, radix ranunculi ternati 9.5g, Rhizoma Sparganii 1g, Chinese olive 30g, tuber of dwarf lilyturf 5g, Radix Astragali 18g, the root of straight ladybell
1g, radix polygonati officinalis 18g, blackberry lily 1g, cicada slough 16g, honeysuckle 11g.
Preparation technology：
Take the taste Chinese medicine of dried rhizome of rehmannia of recipe quantity etc. 12 plus 8 times of decoctings are boiled twice, the time is respectively 1 hour, merge twice
Decocting liquid, filtration, after cooling, plus ethanol to concentration is 40%, stands 24 hours, refluxing extraction three times, and return time is 3h, filter
Cross, filtrate recycling ethanol, be concentrated into medicinal extract, extract dry is into fine powder；Those skilled in the art add in the preparation method technology
Enter appropriate amount of auxiliary materials and be made tablet capsule agent with conventional formulation method, obtain final product.
Embodiment 9
Prescription：Dried rhizome of rehmannia 4g, chrysanthemum indicum 15g, radix ranunculi ternati 5.5g, Rhizoma Sparganii 8g, Chinese olive 10g, tuber of dwarf lilyturf 12g, Radix Astragali 10g, the root of straight ladybell
8g, radix polygonati officinalis 10g, blackberry lily 3g, cicada slough 8g, honeysuckle 25g.
Preparation technology：
Take the taste Chinese medicine of dried rhizome of rehmannia of recipe quantity etc. 12 plus 6 times of decoctings are boiled twice, the time is respectively 3 hours, merge twice
Decocting liquid, filtration, after cooling, plus ethanol to concentration is 80%, stands 12 hours, refluxing extraction three times, and return time is 2h, filter
Cross, filtrate recycling ethanol, be concentrated into medicinal extract, extract dry is into fine powder；Those skilled in the art add in the preparation method technology
Enter appropriate amount of auxiliary materials and be made tablet tablet with conventional formulation method, obtain final product.
The pharmaceutical composition paraxylene of the present invention of embodiment 10 causes the influence of mice ear
Take healthy ICR mouse 50,18-22g, ♀ ♂ half and half, point 5 groups, every group 10, i.e. model group, positive controls
(dexamethasone 20mg/kg), pharmaceutical composition of the present invention (are obtained) by the described pharmaceutical composition prescription of embodiment 1 and preparation technology
Low dose group, middle dose group and high dose group (dosage is 10mg/kg, 30mg/kg, 60mg/kg, by crude drug gauge).Every
Ig is administered once/d, and 14d is administered, and 60min after last medicine, mouse right ear uniform application dimethylbenzene 0.03mL/ only causes to swell, cut after 2h
Lower ears are beaten auricle and are weighed, and calculate ear swelling value (mg).Swelling value=auris dextra weight-left ear weight, the results are shown in Table 1.
The pharmaceutical composition paraxylene induced mice ear swelling of the present invention of table 1 influence (N=10)
Note：Compare with model group, * P ＜ 0.05, * * P ＜ 0.01
Result shows, compares with model group that high, medium and low three dosage groups of pharmaceutical composition of the present invention can be extremely notable
Or the ear swelling value (P ＜ 0.01, P ＜ 0.05) of dimethylbenzene induced mice is significantly reduced, show that pharmaceutical composition of the present invention has
The effect of the mice ear of dimethylbenzene induction is significantly inhibited, and there is significant dose-effect and close in its reducing effect to ear swelling
System.Under same experiment condition, positive control drug is significantly reduced ear swelling value (P ＜ 0.01), but its antiphlogistic effects is substantially too late
Pharmaceutical composition high dose group of the present invention.
The influence that the pharmaceutical composition of the present invention of embodiment 11 is acted on mouse fluid dryness
Take healthy ICR mouse 50,18-22g, ♀ ♂ half and half, random point of 5 groups, every group 10, i.e. model group, positive control
Group (100% polygala decocts night, 20mL/kg), pharmaceutical composition of the present invention (press the described pharmaceutical composition prescription of embodiment 1 and preparation
Technique is obtained) (dosage is respectively 10mg/kg, 30mg/kg, 60mg/kg, by life for low dose group, middle dose group and high dose group
Dose meter).The experiment continuous ig of each group is administered once/d, and 7d, the isometric physiological saline of model group ig is administered.0.5h after last medicine is small
5% phenol red normal saline solution 0.15mL/10g of the fresh configuration of mouse intraperitoneal injection, animal is put to death after injection phenol red solution 0.5h,
After eye socket bloodletting, tracheae surrounding tissue is peelled off, cut one section of tracheae to bronchus crotch under thyroid cartilage, shaken and put
Put overnight, obtain transparent supernatant, with mensuration absorbance value (μ g/mL) at 721 type spectrophotometer 546nm, the results are shown in Table 2.
The pharmaceutical composition of the present invention of table 2 to airway of mice phenols contents influence (N=10)
Note：Compare with model group, * P ＜ 0.05, * * P ＜ 0.01
Above-mentioned experimental result shows, compares with model group, basic, normal, high each dosage group of pharmaceutical composition of the present invention
The phenols contents (P ＜ 0.05, P ＜ 0.01) of mouse tracheae section are significantly improved with notable or pole, shows drug regimen of the present invention
Thing has significant phlegm-dispelling functions, and there is significant dose-effect relationship.Under same experiment condition, positive control drug is also extremely significantly carried
The phenols contents (P ＜ 0.01) of mouse tracheae section high.
Influence of the pharmaceutical composition of the present invention of embodiment 12 to swollen hyperplasia of rat granuloma
Cleaning grade Wistar rats 50 are taken, male and female half and half, body weight 190-210g is randomly divided into model group, medicine of the present invention
(dosage is respectively compositions (being obtained by the described pharmaceutical composition prescription of embodiment 1 and preparation technology) high, medium and low dosage group
10mg/kg, 30mg/kg, 60mg/kg, by crude drug gauge) and positive controls (aspirin 100mg/kg), every group 10.
Model group rats are anesthetized with ether, and osculum is cut at back, and the disinfecting silk or cotton of 10mg will be weighed as with ophthalmic tweezers
Ball is subcutaneous from the implantation of small otch, immediately skin suture.The same modeling of other each test groups, administration is started in operation next day, real
The continuous 7d gastric infusions of each group are tested, once a day.Model group gives isometric physiological saline, and rat is put to death in 8d, opens original and cuts
Mouthful, cotton balls is taken out together with surrounding connective tissue, adipose tissue is rejected, 60 DEG C of drying 12h in baking oven are put, claim dry weight, subtract
Raw cotton ball quality as granuloma net weight is removed, compares the difference of granuloma net weight between each group, experimental result is shown in Table 3.
The pharmaceutical composition of the present invention of table 3 to swollen hyperplasia of rat granuloma influence (N=10)
Note：Compare with model group, * P ＜ 0.05, * * P ＜ 0.01
Compare with model group, the present invention is high, middle dose group and aspirin control group can pole significantly reduce it is granulomatous
Weight (P ＜ 0.01), low dose group significantly reduces granulomatous weight (P ＜ 0.05) and there is significant dose-effect relationship, and this says
Bright pharmaceutical composition of the present invention can be obvious to subacute, chronic inflammation therapeutic effect, especially present invention height, middle dosage.
Claims (6)
1. a kind of pharmaceutical composition for treating pharyngitis, it is characterised in that it is obtained by the raw material of following weight portion：Dried rhizome of rehmannia 4-13g,
Chrysanthemum indicum 11-15g, radix ranunculi ternati 5.5-9.5g, Rhizoma Sparganii 1-8g, Chinese olive 10-30g, tuber of dwarf lilyturf 5-12g, Radix Astragali 10-18g, the root of straight ladybell 1-
8g, radix polygonati officinalis 10-18g, blackberry lily 1-3g, cicada slough 8-16g, honeysuckle 11-25g.
2. pharmaceutical composition as claimed in claim 1, it is characterised in that it is obtained by the raw material of following weight portion：Dried rhizome of rehmannia 9g,
Chrysanthemum indicum 13g, radix ranunculi ternati 7.5g, Rhizoma Sparganii 5g, Chinese olive 20g, tuber of dwarf lilyturf 8g, Radix Astragali 14g, the root of straight ladybell 4g, radix polygonati officinalis 14g, blackberry lily 2g, cicada slough
12g, honeysuckle 18g.
3. pharmaceutical composition as claimed in claim 1 or 2, it is characterised in that it is granule, tablet or capsule.
4. a kind of preparation method of pharmaceutical composition as claimed in claim 3, it is characterised in that it is comprised the following steps：Take place
The 12 taste Chinese medicines such as the dried rhizome of rehmannia of side's amount add 6-8 times of decocting to boil twice, and the time is respectively 1-3 hours, merge decocting liquid twice, filter
Cross, after cooling, plus ethanol to concentration is 40-80%, stands 12-24 hours, and refluxing extraction three times, return time is 2~3h, filter
Cross, filtrate recycling ethanol, be concentrated into medicinal extract, extract dry is into fine powder；Those skilled in the art add in the preparation method technology
Enter appropriate amount of auxiliary materials and clinical institute receptible granule, tablet or capsule are made of conventional formulation method, obtain final product.
5. pharmaceutical composition as claimed in claim 1 or 2 is preparing the purposes in treating pharyngitis medicine.
6. purposes as claimed in claim 5, it is characterised in that the pharyngitis is acute or chronic pharyngitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410539047.5A CN104274746B (en) | 2014-10-14 | 2014-10-14 | Pharmaceutical composition for treating pharyngitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410539047.5A CN104274746B (en) | 2014-10-14 | 2014-10-14 | Pharmaceutical composition for treating pharyngitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104274746A CN104274746A (en) | 2015-01-14 |
| CN104274746B true CN104274746B (en) | 2017-05-24 |
Family
ID=52250407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410539047.5A Active CN104274746B (en) | 2014-10-14 | 2014-10-14 | Pharmaceutical composition for treating pharyngitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104274746B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104606465A (en) * | 2015-03-05 | 2015-05-13 | 陈红 | Medicine for treating acute pharyngitis and preparation method for medicine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102139062A (en) * | 2011-03-29 | 2011-08-03 | 权士珍 | Novel traditional Chinese medicine for treating pharyngitis and tonsillitis |
-
2014
- 2014-10-14 CN CN201410539047.5A patent/CN104274746B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102139062A (en) * | 2011-03-29 | 2011-08-03 | 权士珍 | Novel traditional Chinese medicine for treating pharyngitis and tonsillitis |
Non-Patent Citations (1)
| Title |
|---|
| 中医药治疗慢性咽炎综述;解佳伟等;《山西大同大学学报》;20090628;第25卷(第3期);第57-59页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104274746A (en) | 2015-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN103830535B (en) | Pharmaceutical composition for the treatment of rhinitis and its production and use | |
| CN102284049A (en) | Traditional Chinese medicine compound preparation for resisting ulcer and relieving chemoradiotherapeutic toxic and side effects, and preparation method and application thereof | |
| US20180369308A1 (en) | Chinese herbal medicine composition having a function of relieving hypothyroidism, preparation method and use thereof | |
| CN105055606A (en) | Medicine for treating influenza | |
| CN104398841A (en) | Traditional Chinese medicine preparation for treating cataract and glaucoma and preparation method of traditional Chinese medicine preparation | |
| CN101703684A (en) | Medicament for treating allergic purpura and preparation method thereof | |
| CN103494962B (en) | Traditional Chinese medicine composition capable of clearing heat and detoxifying | |
| CN105381132A (en) | Drug for treating thyroid nodule | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN104274746B (en) | Pharmaceutical composition for treating pharyngitis | |
| CN105055841A (en) | Medicine for treating chronic pharyngitis and preparing method thereof | |
| CN103127272A (en) | Chinese medicinal preparation for treating breast disease and preparation method thereof | |
| CN106511689B (en) | Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal obstruction | |
| CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
| CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| CN110463799A (en) | A kind of wild plant composition of protect liver constipation-relieving tea | |
| CN102805795B (en) | Chinese medicinal composition for treating acute soft tissue injury of chest and hypochondrium and application thereof | |
| CN101380414B (en) | Traditional Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof | |
| CN101879227B (en) | Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof | |
| CN106619870A (en) | Composition for treating digestive system neoplasms, and preparation method of composition | |
| CN101579507A (en) | Medicine for treating gall stones and preparation method thereof | |
| CN105963423A (en) | Pharynx-heat-clearing and larynx-moistening soft capsule preparation and method for preparing pharynx-heat-clearing and larynx-moistening soft capsule preparation | |
| CN105497783A (en) | Application of traditional Chinese medicine preparation to preparing drug for treating qi stagnation and blood stasis type chloasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Qinghao Inventor after: Ma Chunhua Inventor before: Chen Hong |
|
| CB03 | Change of inventor or designer information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170420 Address after: 362000 Huian County, Fujian City, the town of Hong Kong Road Applicant after: HUIAN LIKE TRADE CO.,LTD. Address before: 266000 Qingdao City, Sifang District, Shandong flood water ditch village, No. 2, 106 Applicant before: Chen Hong |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201102 Address after: Peng Lou Zhen Xi Jie, juancheng County, Heze City, Shandong Province Patentee after: Health center of Penglou Town, juancheng County Address before: 362000 Huian County, Fujian City, the town of Hong Kong Road Patentee before: HUIAN LIKE TRADE Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211116 Address after: 274000 No. 7, phase I, Shunwangcheng traditional Chinese medicine industrial park, juancheng County, Heze City, Shandong Province Patentee after: Shandong Huike Pharmaceutical Technology Co.,Ltd. Address before: 274609 Peng Lou Zhen Xi Jie, juancheng County, Heze City, Shandong Province Patentee before: Health center of Penglou Town, juancheng County |
|
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A pharmaceutical composition for treating pharyngitis Effective date of registration: 20211229 Granted publication date: 20170524 Pledgee: Postal Savings Bank of China Limited juancheng County sub branch Pledgor: Shandong Huike Pharmaceutical Technology Co.,Ltd. Registration number: Y2021980017045 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230330 Granted publication date: 20170524 Pledgee: Postal Savings Bank of China Limited juancheng County sub branch Pledgor: Shandong Huike Pharmaceutical Technology Co.,Ltd. Registration number: Y2021980017045 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug combination for treating pharyngitis Granted publication date: 20170524 Pledgee: Shandong juancheng Rural Commercial Bank Co.,Ltd. Plaza sub branch Pledgor: Shandong Huike Pharmaceutical Technology Co.,Ltd. Registration number: Y2024980007729 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |